Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE: LAS41008 vs Fumaderm and Placebo in Psoriasis
NCT01726933Phase 3Completed
- Sponsor
- Almirall
- Start
- Nov 2012
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of dimethyl fumarate in plaque psoriasis (3 arms), sponsored by Almirall. Primary endpoints: Psoriasis Area and Severity Index 75 at 16 weeks and Physician Global Assessment at 16 weeks. Started Nov 2012; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01726933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01726933.